{{Drugbox
| IUPAC_name = (±)-1-[1-(2-methoxyphenyl)-2-phenylethyl]piperidine
| image = Methoxphenidine structure.svg

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_status = Illegal in China and Sweden
| routes_of_administration = Oral, Rectal

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 127529-46-8
| ATC_prefix = 
| ATC_suffix = 
| PubChem =  67833251
| UNII = H2W7A6GZGX
| ChemSpiderID = 52085156
| smiles = COC1=C(C=CC=C1)C(CC2=CC=CC=C2)N3CCCCC3
| StdInChI          = 1S/C20H25NO/c1-22-20-13-7-6-12-18(20)19(21-14-8-3-9-15-21)16-17-10-4-2-5-11-17/h2,4-7,10-13,19H,3,8-9,14-16H2,1H3
| StdInChIKey       = QXXCUXIRBHSITD-UHFFFAOYSA-N

<!--Chemical data-->
| C=20 | H=25 | N=1 | O=1
| molecular_weight = 295.4186 g/mol
}}

'''Methoxphenidine (methoxydiphenidine, 2-MeO-Diphenidine, MXP)''' is a [[Dissociative drug|dissociative]] of the diarylethylamine class that has been sold online as a [[designer drug]].<ref name="Morris">{{cite journal | first1=H. | first2=J. | last1=Morris | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1620/abstract| | title=From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs | last2=Wallach | journal=Drug Testing and Analysis | date=July–August 2014 | volume=6 | issue=7-8 | pages=614–632 | doi=10.1002/dta.1620 | pmid=24678061}}</ref><ref>{{cite journal | author1=Marie Claire Van Hout | url=http://www.tandfonline.com/doi/abs/10.1080/02791072.2014.974002 | title="Word of Mouse": Indigenous Harm Reduction and Online Consumerism of the Synthetic Compound Methoxphenidine | author2=Evelyn Hearne | journal=Journal of Psychoactive Drugs | date=January–March 2015 | volume=47 | issue=1 | pages=30–41 | doi=10.1080/02791072.2014.974002 | pmid=25715070}}</ref> Methoxphenidine was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury.<ref name=Searle>{{cite web | url=https://www.google.com/patents/EP0346791B1 | title=Patent EP 0346791 B1 - 1,2-diarylethylamines for treatment of neurotoxic injury | accessdate=17 June 2015 |author1=Nancy M. Gray |author2=Brian K. Cheng }}</ref> Shortly after the 2013 UK ban on arylcyclohexylamines methoxphenidine and the related compound [[diphenidine]] became available on the gray market, where it has been encountered as a powder and in tablet form.<ref name="McLaughlin">{{cite journal | first1=G. | first10=H. | first11=S. | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1800/abstract | first2=N. | last1=McLaughlin | last10=Morris | last11=Brandt | title=Test purchase, synthesis, and characterization of 2-methoxydiphenidine (MXP) and differentiation from its meta- and para-substituted isomers | last2=Morris | last3=Kavanagh | first3=P. | last4=Power | first4=J. | last5=O'Brien | first5=J. | last6=Talbot | first6=B. | last7=Elliott | first7=S. | last8=Wallach | first8=J. | last9=Hoang | first9=K. | journal=Drug Testing and Analysis | date=January 2016 | volume=8 | issue=1 | pages=98–109 | doi=10.1002/dta.1800| pmid=25873326}}</ref> Though diphenidine possesses higher affinity for the NMDA receptor, anecdotal reports suggest methoxphenidine has greater oral potency.<ref name="Morris"/> Of the three isomeric [[anisole|anisyl]]-substituents methoxphenidine has affinity for the [[NMDA receptor]] that is higher than 4-MeO-Diphenidine but lower than 3-MeO-Diphenidine,<ref name="Searle"/> a [[structure–activity relationship]] shared by the [[arylcyclohexylamine]]s.<ref name="WallachPLOS">{{cite journal | url=http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0157021 | title=Pharmacological Investigations of the Dissociative ‘Legal Highs’ Diphenidine, Methoxphenidine and Analogues | date=June 2016 | author1=Jason Wallach | author2=Heather Kang | author3=Tristan Colestock | author4=Hamilton Morris |author5=Zuner A. Bortolotto | author6=Graham L. Collingridge | author7=David Lodge | author8=Adam L. Halberstadt | author9=Simon D. Brandt | author10=Adeboye Adejare | journal=PLOS ONE | volume=11 | issue=6 | pages=e0157021 | doi=10.1371/journal.pone.0157021 | pmid=27314670 | pmc=4912077}}</ref>

== Side effects ==

Acute methoxphenidine intoxication has been reported to produce confusion, hypertension, and tachycardia that was responsive to treatment with intravenous [[lorazepam]],<ref name="Hofer">{{cite journal | first1=K.E. | last1=Hofer | url=http://informahealthcare.com/doi/abs/10.3109/15563650.2014.974264| | title=Acute toxicity associated with the recreational use of the novel dissociative psychoactive substance methoxphenidine | last2=Degrandi | first2=C. | last3=Müller | first3=D.M. | last4=Zürrer-Härdi | first4=U. | last5=Wahl | first5=S. | last6=Rauber-Lüthy | first6=C. | last7=Ceschi | first7=A. | journal=Clinical Toxicology | date=December 2014 | volume=52 | issue=10 | pages=1288–1291 | doi=10.3109/15563650.2014.974264 | pmid=25350467}}</ref><ref>{{cite journal | url=http://www.tandfonline.com/doi/abs/10.3109/15563650.2015.1033630 | title=Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine |author1=Anders Helander |author2=Olof Beck |author3=Matilda Bäckberg | journal=Clinical Toxicology | date=June 2015 | volume=53 | issue=5 | pages=446–453 | doi=10.3109/15563650.2015.1033630 | pmid=25881797}}</ref> methoxphenidine has also been associated with three published fatalities<ref name="Elliott">{{cite journal | url=http://jat.oxfordjournals.org/content/39/4/287 | title=First Reported Fatalities Associated with the ‘Research Chemical’ 2-Methoxydiphenidine | author1=Simon P. Elliott1 | author2=Simon D. Brandt | author3=Jason Wallach | author4=Hamilton Morris | author5=Pierce V. Kavanagh | journal=Analytical Toxicology | date=May 2015 | volume=39 | issue=4 | pages=287–293 | doi=10.1093/jat/bkv006 | pmid=25698777}}</ref> and one case of [[Driving under the influence|impaired driving]].<ref>{{cite journal | author1=Nicole Stachel | url=https://link.springer.com/article/10.1007/s00414-015-1280-5 | title=A methoxydiphenidine-impaired driver | date=March 2016 | author2=Andrea Jacobsen-Bauer | author3=Gisela Skopp | journal=International Journal of Legal Medicine | volume=130 | issue=2 | pages=405–409 | doi=10.1007/s00414-015-1280-5 | pmid=26482953}}</ref>

Psychotic episodes have also been reported, including a murder in June 2014.<ref>{{cite web | url=http://www.bbc.com/news/uk-northern-ireland-36556909 | title=Man who killed mother believing her to be a witch sentenced to minimum of five years in jail | publisher=BBC News | date=17 June 2016}}</ref>

==Legal status==

As of October 2015 MXP is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>

MXP is also banned in Sweden.<ref>{{cite web | url=http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2015/mars/fler-amnen-foreslas-bli-klassade-som-narkotika-eller-halsofarlig-vara/ | title=Fler ämnen föreslås bli klassade som narkotika eller hälsofarlig vara | publisher=Folkhälsomyndigheten | date=24 March 2015 | language=Swedish | accessdate=21 October 2015}}</ref>

In Canada, MT-45 and its analogues were made Schedule I controlled substances.<ref>{{cite journal | url=http://www.gazette.gc.ca/rp-pr/p2/2016/2016-06-01/html/sor-dors106-eng.php | title=Regulations Amending the Food and Drug Regulations (Parts G and J — Lefetamine, AH-7921, MT-45 and W-18) | author=Denis Arsenault | journal=Canada Gazette | date=1 June 2016 | volume=150 | issue=11 | publisher=Government of Canada}}</ref> Possession without legal authority can result in maximum 7 years imprisonment. Further, [[Health Canada]] amended the ''Food and Drug Regulations'' in May, 2016 to classify MXP as a restricted drug. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the drug.

==See also==
* [[AD-1211]]
* [[Diphenidine]]
* [[Ephenidine]]
* [[Fluorolintane]]
* [[Lanicemine]]
* [[Lefetamine]]
* [[MT-45]]
* [[NMDA receptor antagonist]]
* [[Phencyclidine]]

==References==
{{Reflist|2}}

{{Hallucinogens}}
{{Ionotropic glutamate receptor modulators}}

[[Category:Designer drugs]]
[[Category:Diarylethylamines]]
[[Category:Dissociative drugs]]
[[Category:NMDA receptor antagonists]]
[[Category:Piperidines]]


{{nervous-system-drug-stub}}